Next Article in Journal
Failure of Micractinium simplicissimum Phosphate Resilience upon Abrupt Re-Feeding of Its Phosphorus-Starved Cultures
Previous Article in Journal
Infantile Neurodegeneration Results from Mutants of 17β-Hydroxysteroid Dehydrogenase Type 10 Rather Than Aβ-Binding Alcohol Dehydrogenase
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 10
10.3390/ijms24108488
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

by
Mónica Cejuela
1,*,
Ana Gil-Torralvo
1,2,3,
M. Ángeles Castilla
2,3,
M. Ángeles Domínguez-Cejudo
2,3,
Alejandro Falcón
1,
Marta Benavent
1,2,3,
Sonia Molina-Pinelo
2,3,
Manuel Ruiz-Borrego
1 and
Javier Salvador Bofill
1,2,3,*
1
Medical Oncology Department, Virgen del Rocio Hospital, 41013 Seville, Spain
2
Institute of Biomedicine of Seville (IBiS), HUVR, CSIC, Universidad de Sevilla, 41013 Seville, Spain
3
Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology, 41092 Sevilla, Spain
*
Authors to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(10), 8488; https://doi.org/10.3390/ijms24108488
Submission received: 4 April 2023 / Revised: 2 May 2023 / Accepted: 6 May 2023 / Published: 9 May 2023
(This article belongs to the Section Molecular Oncology)
Browse Figures
Versions Notes

Abstract

By the end of 2020, there were more than 8 million women alive who had received a breast cancer diagnosis in the previous 5 years, making it the most prevalent neoplasia in the world. About 70% of breast-cancer cases present positivity for estrogen and/or progesterone receptors and a lack of HER-2 overexpression. Endocrine therapy has traditionally been the standard of care for ER-positive and HER-2-negative metastatic breast cancer. In the last 8 years, the advent of CDK4/6 inhibitors has shown that adding them to endocrine therapy doubles PFS. As a result, this combination has become the gold standard in this setting. Three CDK4/6 inhibitors have been approved by the EMA and the FDA: abemaciclib, palbociclib, and ribociclib. They all have the same indications, and it is at each physician’s discretion to choose one or the other. The aim of our study was to perform a comparative efficacy analysis of the three CDK4/6i using real-world data. We selected patients diagnosed with endocrine-receptor-positive and HER2-negative breast cancer who were treated with all three CDK4/6i as first-line therapy at a reference center. After 42 months of retrospective follow up, abemaciclib was associated with a significant benefit in terms of progression-free survival in endocrine-resistant patients and in the population without visceral involvement. In our real-world cohort, we found no other statistically significant differences among the three CDK4/6 inhibitors.
Keywords: CDK4/6 inhibitors; cyclin inhibitors; breast cancer; breast carcinoma; metastatic; endocrine therapy; abemaciclib; palbociclib; ribociclib; real world CDK4/6 inhibitors; cyclin inhibitors; breast cancer; breast carcinoma; metastatic; endocrine therapy; abemaciclib; palbociclib; ribociclib; real world

Share and Cite

MDPI and ACS Style

Cejuela, M.; Gil-Torralvo, A.; Castilla, M.Á.; Domínguez-Cejudo, M.Á.; Falcón, A.; Benavent, M.; Molina-Pinelo, S.; Ruiz-Borrego, M.; Salvador Bofill, J. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. Int. J. Mol. Sci. 2023, 24, 8488. https://doi.org/10.3390/ijms24108488

AMA Style

Cejuela M, Gil-Torralvo A, Castilla MÁ, Domínguez-Cejudo MÁ, Falcón A, Benavent M, Molina-Pinelo S, Ruiz-Borrego M, Salvador Bofill J. Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. International Journal of Molecular Sciences. 2023; 24(10):8488. https://doi.org/10.3390/ijms24108488

Chicago/Turabian Style

Cejuela, Mónica, Ana Gil-Torralvo, M. Ángeles Castilla, M. Ángeles Domínguez-Cejudo, Alejandro Falcón, Marta Benavent, Sonia Molina-Pinelo, Manuel Ruiz-Borrego, and Javier Salvador Bofill. 2023. "Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer" International Journal of Molecular Sciences 24, no. 10: 8488. https://doi.org/10.3390/ijms24108488

APA Style

Cejuela, M., Gil-Torralvo, A., Castilla, M. Á., Domínguez-Cejudo, M. Á., Falcón, A., Benavent, M., Molina-Pinelo, S., Ruiz-Borrego, M., & Salvador Bofill, J. (2023). Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer. International Journal of Molecular Sciences, 24(10), 8488. https://doi.org/10.3390/ijms24108488

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop